{
    "clinical_study": {
        "@rank": "40084", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 10 subjects with Plasmodium vivax malaria will receive KAF156 400 mg once a day for three days"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 10 subjects with Plasmodium falciparum malaria will receive KAF156 400mg once a day for three days"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 20 subjects with Plasmodium falciparum malaria will receive single dose of KAF156 800mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria\n      patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400\n      mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)"
        }, 
        "brief_title": "Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": [
                "Malaria", 
                "Malaria, Vivax"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum\n        or P. vivax; Weight between 40 kg to 90 kg.\n\n        Exclusion Criteria:\n\n          -  Patients with signs and symptoms of severe/complicated malaria\n\n          -  Infection with more than one parasite species\n\n          -  Women of child-bearing potential; pregnant or nursing women\n\n          -  Those who have taken any anti-malarial treatment in the preceding 14 days or other\n             investigational drugs within 30 days or 5 half-lives"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753323", 
            "org_study_id": "CKAF156X2201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "KAF156 will be supplied as tablets for oral use.", 
                "intervention_name": "KAF156 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "KAF156 will be supplied as tablets for oral use.", 
                "intervention_name": "KAF156 800 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "acute malaria, KAF156", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10048"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ratchabari", 
                        "country": "Thailand", 
                        "zip": "70180"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Srisaket", 
                        "country": "Thailand", 
                        "zip": "33140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Srisaket", 
                        "country": "Thailand", 
                        "zip": "33150"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tak", 
                        "country": "Thailand", 
                        "zip": "63110"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tak", 
                        "country": "Thailand", 
                        "zip": "63110"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tak", 
                        "country": "Thailand", 
                        "zip": "63140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hanoi", 
                        "country": "Vietnam", 
                        "zip": "10000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Taiwan", 
                "Thailand", 
                "Vietnam"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Institute for Development of Human Research Protection (IHRP)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change in calculated parasite count in blood, using thin film, thick film and blood density assessments.", 
                "measure": "Parasite clearance time", 
                "safety_issue": "No", 
                "time_frame": "baseline and up to 5 days"
            }, 
            {
                "description": "Percent of patients with blood parasite count of zero after 28 days of treatment.", 
                "measure": "28-day cure rate", 
                "safety_issue": "No", 
                "time_frame": "day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753323"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ECGs will be monitored at 3 hours post dose on day 1; pre-dose, and 3 hours post dose on Day 2; pre-dose, 3, 5, 24, 48 hours post dose on Day 3 and at study completion.", 
                "measure": "ECG monitoring", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1, 2, 3 and 5"
            }, 
            {
                "description": "Change in AUC 0-24h will be analyzed using parent drug in plasma samples. On Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Area under the curve (AUC) 0-24h", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 3"
            }, 
            {
                "description": "Change in accumulation ratio will be analyzed using parent drug in plasma samples. On Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Accumulation ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1)", 
                "safety_issue": "No", 
                "time_frame": "Day s 1 and 3"
            }, 
            {
                "description": "Changes in Cmax will be analyzed using parent drug in plasma samples. On Day 1 of Part 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 3 (Part 1); Day 1 (Part 2)"
            }, 
            {
                "description": "Change in Tmax will be analyzed using parent drug in plasma samples. On Day 1 of Part 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Time to maximum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 3 of (Part 1); Day 1 (Part 2)"
            }, 
            {
                "description": "Changes in half life will be analyzed using parent drug in plasma samples. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Half-life (T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 3 (Part 1); Day 1 (Part 2)"
            }, 
            {
                "description": "Changes inCL/F will be analyzed using parent drug in plasma samples . On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Clearance (CL/F )", 
                "safety_issue": "No", 
                "time_frame": "Day 3 (Part 1); Day 1 (Part 2)"
            }, 
            {
                "description": "Changes in apparent volume of distribution will be analyzed using parent drug in plasma samples. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Apparent volume of distribution during the terminal elimination phase following extravascular administrationi(Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 3 of Part 1; Day 1 of Part 2"
            }, 
            {
                "description": "Changes in AUC -last will be analyzed using parent drug in plasma samples. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Area under the curve (AUC) last", 
                "safety_issue": "No", 
                "time_frame": "Day 3 (Part 1); Day 1 (Part 2)"
            }, 
            {
                "description": "Changes in AUC 0-t will be analyzed using parent drug in plasma samples On Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Area under the curve (AUC) 0-t", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Part 2)"
            }, 
            {
                "description": "Changes in AUC inf will be analyzed using parent drug in plasma samples. On Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose", 
                "measure": "Area under the curve (AUC) inf", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Part 2)"
            }, 
            {
                "description": "Changes in hematology will be measured.", 
                "measure": "Lab evaluation - hematology", 
                "safety_issue": "Yes", 
                "time_frame": "Days 2, 3, 5, study completion"
            }, 
            {
                "description": "Changes in blood chemistry will be measured.", 
                "measure": "Lab evaluation - blood chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "Day 2, 3, 5, study completion"
            }, 
            {
                "description": "Changes in urinalysis will be measured", 
                "measure": "Lab evaluation - urinalysis", 
                "safety_issue": "Yes", 
                "time_frame": "Day 2, 3, 5, study completion"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}